ASCO 2022
MEETING ABSTRACT

CORE-002, Phase 1b/2 CG0070 plus nivolumab combo in MIBC demonstrated 54% Pathological Complete Response Rate

ASCO 2022
MEETING ABSTRAC

CORE-001, Phase 2 CG0070 plus pembrolizumab combo in NMIBC demonstrated 92% Complete Response Rate at Any Time

AACR 2022
MEETING ABSTRACT

CORE-001, Phase 2 CG0070 plus pembrolizumab combo in NMIBC demonstrated 100% Complete Response Rate at 3 Months in 10 patients.

SITC 2021
POSTER

CORE-001, Phase 2 CG0070 plus pembrolizumab combo in NMIBC demonstrated 100% Complete Response Rate at 3 Months in 7 patients (pdf)

AUA 2021
MEETING ABSTRACT

CORE-001, Phase 2 CG0070 plus pembrolizumab combo in NMIBC demonstrated 100% Complete Response Rate at 3 Months in 5 patients (pdf)

SUO 2020
POSTER

BOND-003, Phase 3 CG0070 monotherapy pivotal trial in BCG-unresponsive NMIBC (pdf)

2018 AUA
MEETING ABSTRACT

BOND-002, Phase 2 CG0070 monotherapy trial in BCG-unresponsive NMIBC Interim Analysis of 12-month Results (pdf)

2017 AUA
MEETING ABSTRACT

BOND-002, Phase 2 CG0070 monotherapy trial in BCG-unresponsive NMIBC Demonstrated 6-month Complete Response Rate of 44% in Interim Analysis (pdf)

Phase 2 CG 00700 Safety and Efficacy StudyInterim results: Overall 6-month CR was 47% and patients with pure T1 showed a CR at 6 months (pdf)

UROLOGIC ONCOLOGY 2017

Oncolytic viruses are novel immunotherapeutic agents with a two-pronged approach (pdf)

FRONTIERS IN ONCOLOGY 2014

CG0070 Phase 1 dose-escalation study (pdf)

MOLECULAR THERAPY 2006

CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor-Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer (pdf)

CANCER THERAPY 2006